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In Brief
Wang et al. (2013) proposed that the BLM
helicase and TopBP1 interact via
phosphorylated Ser338 of BLM, and that
TopBP1 shields BLM from degradation.
In contrast, Blackford et al. reveal that the
BLM-TopBP1 interaction involves Ser304
of BLM, not Ser338, and that TopBP1 has
no role in stabilizing BLM.
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The Bloom syndrome helicase BLM and topoisomer-
ase-IIb-binding protein 1 (TopBP1) are key regulators
of genome stability. It was recently proposed that
BLM phosphorylation on Ser338 mediates its inter-
action with TopBP1, to protect BLM from ubiquityla-
tion and degradation (Wang et al., 2013). Here, we
show that the BLM-TopBP1 interaction does not
involve Ser338 but instead requires BLM phosphory-
lation on Ser304. Furthermore, we establish that
disrupting this interaction does not markedly affect
BLM stability. However, BLM-TopBP1 binding is
important for maintaining genome integrity, because
in its absence cells display increased sister chro-
matid exchanges, replication origin firing and chro-
mosomal aberrations. Therefore, the BLM-TopBP1
interaction maintains genome stability not by con-
trolling BLM protein levels, but via another as-yet
undeterminedmechanism. Finally, we identify critical
residues that mediate interactions between TopBP1
and MDC1, and between BLM and TOP3A/RMI1/
RMI2. Taken together, our findings provide molecu-
lar insights into a key tumor suppressor and genome
stability network.
INTRODUCTION
TopBP1 is an essential protein with key roles in DNA replication
and DNA damage responses (Wardlaw et al., 2014). It has no
known enzymatic activity but contains nine BRCT domains
and a C-terminal region that can stimulate the ATR checkpoint
kinase (Kumagai et al., 2006). While most BRCT domains are
phosphoprotein binding modules, some can interact in a phos-
phorylation-independent manner or recognize other molecules
such as poly(ADP)ribose or DNA (Leung and Glover, 2011).
TopBP1 has multiple binding partners for some of its BRCT do-
mains, indicating that it exists in several discrete complexes.MolecTopBP1-interacting proteins that have been reported to bind
to specific BRCT domains include RAD9, Treslin, and NBS1 to
TopBP1 BRCT1 (Delacroix et al., 2007; Kumagai et al., 2010;
Lee et al., 2007; Yoo et al., 2009); 53BP1 and MDC1 to
BRCT5 (Cescutti et al., 2010; Wang et al., 2011); and FANCJ
(also known as BRIP1) to BRCT7 (Gong et al., 2010), although
the mechanistic roles that these interactions play in TopBP1
functions are not yet clear.
Bloom syndrome is a rare autosomal recessive disorder
caused by mutations in the gene encoding the BLM helicase,
and is characterized by growth retardation, immunodeficiency,
hypersensitivity to sunlight, and cancer predisposition (Bizard
and Hickson, 2014). Cells fromBloom syndrome patients display
multiple signatures of genome instability, including increased
sister chromatid exchanges (SCEs) and chromosomal abnor-
malities (Chaganti et al., 1974; German et al., 1965). BLM per-
forms its functions in a complex with topoisomerase IIIa
(TOP3A), RMI1, and RMI2, which together form a ‘‘dissolva-
some’’ complex capable of resolving homologous recombina-
tion (HR) intermediates to prevent genetic crossover events
(Bizard and Hickson, 2014). Accordingly, BLM may act as a
tumor suppressor primarily by preventing crossovers between
homologous chromosomes that could lead to loss of heterozy-
gosity. BLM also contributes to DNA-end resection to produce
single-stranded DNA tracts for HR (Gravel et al., 2008), and
BLM-deficient cells display DNA replication fork instability and
excessive origin firing, indicating that BLM is an important
regulator of replication dynamics (Davies et al., 2007; Rao
et al., 2007).
We identified BLM as a TopBP1-interacting protein and found
that BLM binding requires BRCT domain 5 of TopBP1, in agree-
ment with a recent report (Wang et al., 2013). However, we
demonstrate that phosphorylated Ser304 of BLM is in fact the
target of this BRCT domain, rather than Ser338, as proposed
by Wang et al. Also in contrast to that report, we find that neither
TopBP1 loss nor disruption of the BLM-TopBP1 interaction has
any discernible effect on BLM protein stability. Importantly, we
establish that BLM-TopBP1 binding promotes genome stability,
as disrupting the interaction in cells leads to increases in SCEs,
replication origin firing, and chromosomal aberrations. Taken
together, we conclude that although TopBP1 cooperates withular Cell 57, 1133–1141, March 19, 2015 ª2015 Elsevier Inc. 1133
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Figure 1. BLM Interacts with TopBP1 via
BRCT5
(A) TopBP1 immunoprecipitates from 293FT cell
extracts contain BLM.
(B) BLM immunoprecipitates from 293FT cell ex-
tracts contain TopBP1.
(C) Schematic showing TopBP1 BRCT domain
layout. Black numbered boxes represent BRCT
domains. K154, K704, and K1317 are the key
phosphopeptide binding lysines in BRCT domains
1, 5, and 7, respectively. The names of known
TopBP1-binding partners are shown below the
BRCT domains they interact with.
(D) Effect of point mutations in TopBP1 BRCT do-
mains 1, 5, and 7 on its binding to NBS1, MDC1,
FANCJ, and BLM compared to wild-type (WT). Pull-
downs were carried out from 293FT cells transiently
transfected with the indicated plasmids 24 hr later.
(E) Effect of two different point mutations in
TopBP1-BRCT5 on binding to MDC1 and BLM.
NBS1 and FANCJ are positive controls as they bind
to TopBP1 BRCT domains 1 and 7, respectively.
(F) Mutation of TopBP1-BRCT5 abrogates binding
to Bloom syndrome complex members. See also
Figure S1.BLM to maintain genome stability, it does so not by maintaining
BLM protein levels, but via a different, as-yet-undefined
mechanism.RESULTS
BLM Interacts with TopBP1 via BRCT5
We identified BLM as a candidate TopBP1 interactor by mass
spectrometric analyses of TopBP1-associated proteins (see Fig-
ure S1 available online). To validate this interaction, we carried
out coimmunoprecipitations from cell extracts and found that
we could readily detect BLM by western blotting of TopBP1 im-
munoprecipitates (Figure 1A). Consistent with this, TopBP1 was
detected in reciprocal BLM immunoprecipitates from cell ex-1134 Molecular Cell 57, 1133–1141, March 19, 2015 ª2015 Elsevier Inc.tracts (Figure 1B), thus confirming that
the two proteins likely exist in a complex
together in cells.
To gain insight into the function of the
BLM-TopBP1 interaction, we needed to
map their reciprocal binding sites. Usually,
one BRCT in a tandem unit contains a
conserved lysine residue that directly con-
tacts the phosphate group of a modified
protein ligand (Leung and Glover, 2011).
Accordingly, mutating such a lysine
drastically reduces ligand-binding affinity.
In TopBP1, these residues are Lys154 in
BRCT1, Lys704 in BRCT5, and Lys1317
in BRCT7 (Cescutti et al., 2010). We
therefore designed GFP-tagged TopBP1
constructs containing lysine-to-alanine
mutations in BRCT domains 1, 5, and 7(Figure 1C), as we considered that these domains were most
likely to mediate the BLM interaction. To validate this approach,
we probed for the presence of previously reported TopBP1-
binding proteins whose interactions have been mapped to
defined BRCT domains (Figure 1D). As expected, mutation of
BRCT1 specifically prevented NBS1 binding (Yoo et al., 2009),
and mutation of BRCT7 inhibited FANCJ binding (Gong et al.,
2010). However, MDC1 binding was apparently unaffected by
mutating TopBP1-BRCT5; note that we used a validated anti-
body that specifically recognizes MDC1 (Stewart et al., 2003).
This was unexpected based on a previous report showing a
requirement for this domain in mediating the TopBP1-MDC1
interaction (Wang et al., 2011). Furthermore, when we analyzed
one of the same TopBP1-BRCT5 mutants used in that report
(W711R), we found that it behaved identically to a Lys704
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Figure 2. BLM Ser304 Phosphorylation Me-
diates Direct Binding to TopBP1-BRCT5
(A) Schematic of the GFP-tagged BLM constructs
used in this study.
(B) The N-terminal 132 residues of BLM are
required for binding to TOP3A and RMI2 but not
TopBP1. Pull-downs were carried out from 293FT
cells transiently transfected with the indicated
plasmids.
(C) The binding site for TopBP1 is located within
residues 133–587 of BLM. RMI2 is a positive
control for binding to the N terminus of BLM.
(D) Sequence alignment showing the evolutionary
conservation of the BLM region containing Ser304
and Ser338.
(E) Mutation of Ser304 specifically abrogates
binding to TopBP1. Pull-downs were carried out
from U2OS cells stably expressing the indicated
proteins.
(F) The BLM-pS304 antibody does not recognize
BLM-S304A. 293FT cells were transiently trans-
fected with the indicated plasmids. NBS1 is a
loading control.
(G) Ser304 is phosphorylated in vivo. BLM immu-
noprecipitates fromU2OS cells weremock treated
or treated with lambda phosphatase (l-PPase).
(H) BLM residues 297–311 are sufficient for inter-
action with TopBP1 when Ser304 is phosphory-
lated. Streptavidin beads were incubated with
biotinylated peptides before addition to HeLa nu-
clear extracts for pull-downs.
(I) TopBP1 BRCT domains 4 and 5 interact directly
with BLM peptides phosphorylated on Ser304.
Streptavidin beads were incubated with bio-
tinylated peptides before mixing with GST-tagged
BRCT domains 4 and 5 or GST alone. See also
Figure S2.mutant, in that it did not affect MDC1 interaction (Figure 1E).
Instead, MDC1 behaved as NBS1 in its binding profile, indicating
that MDC1 in fact interacts with TopBP1 via BRCT1. This con-
clusion is consistent with the observations that most cellular
MDC1 associates with the MRE11-RAD50-NBS1 (MRN) com-
plex (Goldberg et al., 2003) and that TopBP1-BRCT1 is needed
for binding to this complex, and with the suggestion that
MDC1 could mediate TopBP1-MRN interactions (Yoo et al.,
2009).
We next assessed whether any of our TopBP1 BRCT mutants
were compromised in their ability to interact with BLM. Strikingly,
only BRCT5 mutants lost the ability to bind BLM (Figures 1D andMolecular Cell 57, 1133–11411E), thus confirming that this BRCT
domain mediates the TopBP1-BLM inter-
action, and suggesting that a phosphory-
lated residue in BLM or an associated
protein might mediate this interaction.
To explore whether TopBP1 is a compo-
nent of the BLM dissolvasome, we exam-
ined binding of the other members of this
complex (TOP3A, RMI1, and RMI2) to
TopBP1. Like BLM, all these proteins in-
teracted with wild-type TopBP1, but notwith the BRCT5 mutant (Figure 1F), thus indicating that TopBP1
is a member of the dissolvasome complex.
BLM Ser304 Phosphorylation Mediates a Direct
Interaction with TopBP1
To establish whether BLM itself or one of its binding partners was
mediating BLM-TopBP1 binding, we took advantage of the fact
that the N-terminal 132 residues of BLM are required for its inter-
action with the dissolvasome (Hu et al., 2001). Importantly, delet-
ing this region led to the expected abrogation of TOP3A and
RMI2 binding, but TopBP1 binding was unaffected (Figures 2A
and 2B). This result indicated that TopBP1 can associate with, March 19, 2015 ª2015 Elsevier Inc. 1135
BLM in the absence of other dissolvasome members, thereby
strongly implicating BLM as the mediator of TopBP1 binding to
this complex.
To determine the region of BLM that binds TopBP1, we exam-
ined binding of TopBP1 to a series of GFP-tagged BLM trunca-
tion mutants (Figure 2A). These studies showed that a BLM
N-terminal region encompassing residues 133–587 was neces-
sary for TopBP1 binding (Figure 2C). This region of BLM is not
well conserved overall in vertebrates and may therefore be
largely unstructured, but we noticed within it a potentially phos-
phorylatable motif centered on a highly conserved serine residue
(Ser304 in human BLM; Figures 2D and S2). As BRCT domains
can interact with phosphorylated proteins, we examinedwhether
this residue was necessary for TopBP1 binding. Strikingly,
mutating BLM Ser304 to alanine abolished TopBP1 binding but
had no discernible effect on interaction between BLM and
RMI2 (Figure 2E). These results thus established that Ser304 is
specifically required for BLM to interact with TopBP1, and sug-
gested that this residue might be phosphorylated. In accord
with these findings and the predicted phospho-dependent na-
ture of BLM-TopBP1 binding, when we used a phospho-specific
antibody raised against a phosphopeptide encompassing
BLM-Ser304 (Leng et al., 2006), it recognized wild-type BLM,
but not the BLM S304A mutant (Figure 2F). Consistent with
this site being phosphorylated in cells, the antibody detected
endogenous BLM immunoprecipitated from cells in a manner
that was inhibited by phosphatase treatment (Figure 2G).
To investigate whether the TopBP1-BLM interaction was
direct, we used biotinylated nonphosphorylated peptides or
Ser304-phosphorylated BLM peptides in interaction studies.
Importantly, only the phosphopeptide retrieved TopBP1 from
nuclear extracts (Figure 2H), indicating that this conserved motif
in BLM is sufficient to mediate the TopBP1 interaction when
phosphorylated on Ser304. In addition, recombinant GST-
tagged TopBP1 protein comprising BRCT domains 4 and 5
bound to the phosphorylated Ser304 peptide, but not the non-
phosphorylated peptide, whereas GST alone bound to neither
(Figure 2I). Taken together with our other findings, these results
established that the TopBP1-BLM interaction involves direct
binding of phosphorylated BLM-Ser304 to TopBP1-BRCT5.
Ser338 of BLM Is Not Required for TopBP1 Binding
Our conclusion that Ser304 is the critical residue of BLM that
interacts with TopBP1 BRCT domain 5 differed from that of a
recent report describing a role for Ser338 in this binding (Wang
et al., 2013). We initially considered that our respective studies
were not necessarily in disagreement, since it might have been
that phosphorylation of multiple residues was required for the
BLM-TopBP1 interaction. We therefore tested whether we could
replicate a role for BLM-Ser338 inmediating TopBP1 binding. To
do this, we expressed GFP-tagged wild-type BLM or derivatives
in which Ser304 or Ser338 was mutated to alanine (S304A
and S338A, respectively) in cells and assessed their abilities to
retrieve endogenous TopBP1 from cell extracts (Figure 3A).
In contrast to BLM-S304A, the S338A mutant behaved as wild-
type in its ability to bind TopBP1, indicating that Ser338 is not
required for the BLM-TopBP1 interaction. Analyses using cells
synchronized in S phase produced similar results (Figure S3A).1136 Molecular Cell 57, 1133–1141, March 19, 2015 ª2015 Elsevier IWe considered the possibility that the contradictions between
our results and those of Wang et al. might be due to the different
methodologies used. We therefore incubated recombinant
GST-tagged TopBP1-BRCT5 purified from bacteria with lysates
from human cells transfected with plasmids expressing S/Flag/
streptavidin-binding peptide (SFB) triple-tagged BLM as
described in the previous study (Wang et al., 2013). Notably,
the wild-type SFB-BLM and its S304A and S338A mutant
derivatives behaved in the same manner as the respective
GFP-tagged proteins with regard to TopBP1 binding, in that
wild-type and S338A BLM bound to GST-BRCT5 in similar
amounts, whereas the S304A mutant was severely compro-
mised in this regard (Figure 3B).
Next, we examined the relative abilities of peptides en-
compassing phosphorylated or nonphosphorylated Ser304 or
Ser338 of BLM to interact with GST-BRCT5. While the phos-
pho-S304 peptide readily bound the TopBP1 fusion protein,
neither the phospho-S338 peptide nor the nonphosphorylated
peptides were able to interact with it detectably (Figure 3C).
Taken together, our findings thus established that BLM
Ser304, not Ser338, binds to BRCT domain 5 of TopBP1.
The BLM-TopBP1 Interaction Promotes
Genome Stability
BLM-deficient cells display characteristically high levels of SCEs
(Chaganti et al., 1974). To address the potential biological func-
tion of BLM-TopBP1 binding, we tested whether the interaction
was required to suppress SCEs. First, we examined the pheno-
types of U2OS cells stably expressing wild-type or the K704E
BRCT5 mutant TopBP1 and treated with an siRNA targeting
the TopBP1 30 untranslated region (UTR) to deplete the endoge-
nous protein (Figure S3B). Notably, cells expressing TopBP1-
K704E displayed significantly elevated SCEs compared to cells
expressing wild-type TopBP1 (Figure 3D). Next, we employed
BLM/ chicken DT40 cells as a complementation system by
stably transfecting these with vectors encoding wild-type BLM
or BLM-S251A (equivalent to S304A in human BLM; Figure 2D).
We confirmed that the BLM-S251A mutation abrogated TopBP1
binding (Figure S3C), thus revealing that the BLM-TopBP1 inter-
action is highly conserved in vertebrates. As expected, BLM/
cells displayed significantly higher levels of SCEs than BLM+/+
cells. Importantly, this phenotype was fully reversed by reintro-
ducing wild-type BLM but not the S251A mutant in multiple
clones (Figure 3E). These findings therefore established that
the BLM-TopBP1 interaction contributes to suppression of
SCEs in vertebrates.
Replication origins in BLM-deficient cells fire more frequently
than in wild-type cells, probably as a consequence of problems
in replication fork dynamics (Davies et al., 2007; Rao et al., 2007).
We therefore examined whether cells in which BLM-TopBP1
binding is disrupted were similarly defective in this process by
using DNA fiber analyses. Compared to cells expressing wild-
type BLM,we detected significantly higher origin firing inBLM/
cells aswell as in cells expressing BLM-S251A (Figure 3F). These
data thus further supported the notion that interaction with
TopBP1 is required for BLM to function properly.
As BLM-deficient cells display increased chromosomal aber-
rations (German et al., 1965), we investigated whether this wasnc.
A B
C
D
E
F G
Figure 3. The BLM-TopBP1 Interaction
Promotes Genome Stability and Requires
Ser304 but Not Ser338 of BLM
(A) Mutation of BLM Ser338 to alanine does not
affect its interaction with endogenous TopBP1.
Pull-downs were carried out from 293FT cells
transiently transfected with the indicated plas-
mids.
(B) Mutation of BLM Ser338 to alanine does not
affect its interactionwith recombinant GST-tagged
TopBP1-BRCT5. Pull-downs were carried out
using GST proteins bound to glutathione beads
incubated with lysates from 293FT cells transiently
transfected with the indicated plasmids.
(C) TopBP1-BRCT5 interacts directly with BLM
peptides encompassing phosphorylated Ser304
but not Ser338. Streptavidin beads were incu-
bated with biotinylated peptides before mixing
with GST-tagged BRCT5 or GST alone.
(D) Analysis of SCEs in U2OS cells depleted of
endogenous TopBP1 with siRNAs targeting the 30
UTR and expressing wild-type or K704E TopBP1.
A minimum of 20 metaphases was scored per
experiment. Significance was determined using
the Mann-Whitney U test.
(E) Analysis of SCEs in DT40 cells. A minimum of
50 metaphases was scored per experiment. Sig-
nificancewas determined using theMann-Whitney
U test. ‘‘cl.,’’ clone.
(F) DNA fiber analyses to measure origin firing.
DT40 cells were treated with 2.5 mM camptothecin
for 90 min in the presence of IdU, washed, and
then released into drug-free medium containing
CldU for 15 min. A minimum of 200 fibers were
scored per experiment. Mean values of three
independent experiments are shown ± SEM.
Significance was determined using Student’s
two-tailed t test.
(G) Analysis of chromosomal aberrations. Mitotic
spreads were prepared from DT40 cells treated
with 2 mM aphidicolin for 12 hr. A minimum of
35 metaphases was scored per experiment.
Significance was determined using Mann-Whitney
U test. See also Figure S3.also the case in cells in which BLM-TopBP1 binding was disrup-
ted. This revealed that there was a significant increase in the
frequency of such aberrations in BLM/ cells after aphidicolin
treatment, which was corrected by expression of wild-type
BLM but only partially with BLM-S251A (Figure 3G). Taken
together, these data confirmed that the BLM-TopBP1 interaction
is important for maintenance of genome stability.
TopBP1 Does Not Protect BLM from Degradation
It was suggested that BLM interaction with TopBP1 is required
to prevent ubiquitylation and subsequent proteasomal degrada-Molecular Cell 57, 1133–1141tion of BLM (Wang et al., 2013). We there-
fore assessed whether we could also
observe BLM destabilization in absence
of TopBP1. To do this, we first verified
that our BLM antibody was specific by
showing that it recognized a protein spe-cies that is absent in Bloom syndrome cells and in cells treated
with an siRNA targeting the BLM mRNA (Figures S4A and
S4B). We then transfected cells with TopBP1 siRNAs with
sequences that were identical to those used by Wang et al., as
well as two additional ones of our own design. Strikingly, all
four siRNAs depleted TopBP1 to near-undetectable levels in
HeLa cells but had no appreciable effect on BLM protein stability
(Figure 4A). Similar results were obtained in U2OS cells (data not
shown), suggesting that TopBP1 plays no discernible role in
regulating BLM levels. To seek to confirm this, we used an alter-
native method to reduce TopBP1 expression in cells. Some, March 19, 2015 ª2015 Elsevier Inc. 1137
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Figure 4. TopBP1 Does Not Protect BLM from Degradation
(A) TopBP1 depletion does not affect BLM levels. HeLa cells were transfected with the indicated siRNAs and harvested for western blotting 3 days later.
(B) Adenovirus-induced proteasomal degradation of TopBP1 does not affect BLM levels. U2OS cells were infected with the hr703 adenovirus and harvested at
the indicated times for western blotting. E1A is a control for adenovirus infection.
(C) BLM-TopBP1 interaction does not maintain BLM stability. Cycloheximide (CHX) was added to U2OS cells stably expressing GFP-BLM proteins for the
indicated times before harvesting for western blotting. The graph shows the level of BLM at the time points indicated as a percentage of untreated (0 h).
Quantification was performed using ImageJ.
(D) Sequence alignment showing the evolutionary conservation of the BLM region containing Lys38, Lys39, and Lys40.
(E) Mutation of BLM Lys38, Lys39, and Lys40 to alanine (K3A) disrupts binding to TOP3A and RMI2. 293FT cells were transfected with the indicated plasmids and
harvested for pull-downs 24 hr later. See also Figure S4.human adenoviruses promote TopBP1 degradation in infected
cells by hijacking a Cullin-based E3 ubiquitin ligase with the viral
E4orf6 protein and directing it toward TopBP1 (Blackford et al.,
2010). We therefore used one such virus, hr703, to examine
BLM levels during infection. Although TopBP1 was rapidly
and almost completely degraded in cells infected with hr703,
BLM levels actually increased slightly (Figure 4B). Finally,
we compared the half-lives of wild-type and S304A BLM in
cells treated with the translation inhibitor, cycloheximide.
Ensuing results demonstrated that the half-lives of both proteins1138 Molecular Cell 57, 1133–1141, March 19, 2015 ª2015 Elsevier Iwere roughly equivalent, with the S304A mutant in fact being
slightly more stable (Figure 4C). Synchronization of cells in
S phase yielded similar results (Figure S4C). Based on these
experiments, we concluded that TopBP1 plays no significant
role in controlling BLM protein levels.
Wang et al. suggested that BLM degradation might be neces-
sary in G1 cells to prevent DNA-end resection and initiation
of HR in the absence of a sister chromatid. This was based
on their observations that cells stably overexpressing mutant
nondegradable BLM with three N-terminal lysines (Lys38,nc.
Lys39, and Lys40) mutated to alanine (‘‘K3A’’) were hypersensi-
tive to ionizing radiation, showed increased phosphorylation
of CHK1 and RPA, and had a reduced frequency of random
plasmid integration (Wang et al., 2013). Notably, lysines 38, 39,
and 40 are conserved in most vertebrate BLM proteins (Fig-
ure 4D) and lie within the region required for BLM association
with TOP3A and RMI1/2 (Figures 2A–2C). We therefore consid-
ered the possibility that the BLM K3A mutant was compromised
in its binding to the dissolvasome. To test this, we compared
binding of TOP3A and RMI2 to wild-type and K3A BLM (Fig-
ure 4E). We first noted that the K3A mutant was expressed at
similar levels to wild-type BLM, suggesting that lysines 38, 39,
and 40 do not control BLM turnover. Moreover, we found
that substantially less TOP3A and RMI2 was associated with
the K3A mutant compared to wild-type BLM. Therefore, we
concluded that it is not possible to determine whether pheno-
types seen in cells expressing BLM-K3A are due to the inability
of this protein to associate with the dissolvasome, or because
it cannot be ubiquitylated.
DISCUSSION
In this study, we identified and characterized the interaction
between the Bloom syndrome helicase BLM and TopBP1, and
investigated the consequences for cells when binding is disrup-
ted. We found that BLM interacts directly with BRCT domain
5 of TopBP1 via a phosphorylated N-terminal residue (Ser304
in human BLM). This finding was surprising, given a recent
report suggesting that Ser338was important for TopBP1 binding
(Wang et al., 2013). However, we note that Ser338 and its
surrounding amino acid residues are not well conserved
even in most mammals, but Ser304 and surrounding residues
have been highly conserved throughout vertebrate evolution
(Figure 2D). Accordingly, using similar assays and identical
reagents in many cases to those employed by Wang et al., we
clearly established that Ser338 does not play a major role
in BLM-TopBP1 binding. Therefore, we conclude that it is
phosphorylated Ser304, not Ser338, that interacts directly with
TopBP1-BRCT5 in cells.
Significantly, while Wang et al. showed that TopBP1-BRCT5
mutations lead to increased SCEs as we did, they did not
show this phenotype for cells expressing BLM-S338A. By
contrast, we clearly observed increased SCEs in multiple
BLM/ clones stably expressing BLM-S251A (the chicken
equivalent of S304A). We also tested whether we could recapit-
ulate another claim by Wang et al., that TopBP1 stabilizes BLM,
but we were unable to do so. In our hands, BLM stability was
normal in absence of TopBP1 using various methods, including
when we used identical siRNA sequences to deplete TopBP1
in the same cell lines used by Wang et al. In addition, mutant
BLM that cannot interact with TopBP1 was not less stable in
our studies. Taken together, these data strongly suggest that
TopBP1 binding does not protect BLM from proteasomal degra-
dation, and that the BLM-TopBP1 interaction therefore main-
tains genome stability via another mechanism.
Our data cannot rule out an indirect role for TopBP1 in main-
taining BLM stability, because they leave open the formal possi-
bility that our TopBP1 siRNA depletions were not as efficientMolecas those of Wang et al. Crucially, however, under experimental
conditions where we observed increased SCEs in TopBP1-
depleted cells, there was no effect on endogenous BLM protein
stability. Thus, even if TopBP1 has some indirect role inmaintain-
ing BLM stability that we could not detect due to incomplete
TopBP1 depletion (a possibility we consider unlikely), this would
still not explain the chromosomal instability phenotypes we see
in TopBP1-depleted cells or cells expressing BLM or TopBP1
binding mutants.
It was reported that ubiquitylation of lysines 38, 39, and/or 40
in BLM leads to its degradation, that this is prevented by
TopBP1 binding, and that cells expressing BLM with these sites
mutated (‘‘K3A’’) show signs of increased DNA-end resection in
G1 (Wang et al., 2013). These three residues are quite well
conserved in vertebrate BLM, but in some organisms they are
replaced by arginine, suggesting that it is the positive charge
on these residues that is functionally important rather than
their ability to be ubiquitylated. Accordingly, we found that
lysines 38, 39, and 40 of BLM do not obviously affect its protein
levels. Instead, we found that the K3A mutant protein was
defective in its association with dissolvasome components,
which are required for BLM to promote DNA-end resection
(Daley et al., 2014). We thus conclude that any defects
observed in cells expressing the K3A BLM mutant could be
due to lack of binding to the dissolvasome rather than its
inability to be ubiquitylated.
A number of issues arise from our work that will be worthwhile
to address in future studies. In particular, it remains to be
determined which kinase phosphorylates BLM on Ser304 to pro-
mote its interaction with TopBP1, and how it is regulated. Finally,
given that cells expressing mutant BLM that cannot bind
TopBP1 display increased SCEs and chromosomal aberrations,
our data may have important implications for understanding
the increased cancer susceptibility and pathologies observed
in Bloom syndrome patients.EXPERIMENTAL PROCEDURES
Cells and Chemicals
293FT, HeLa, U2OS, and DT40 cells were grown as described previously
(Blackford et al., 2012). Wild-type (JB1) and Bloom syndrome (GM03403)
lymphoblastoid cell lines (LCLs) were grown in RPMI-1640 (Sigma-Aldrich)
supplemented with 10% fetal calf serum and 13 penicillin-streptomycin-
glutamine (Life Technologies). Stable U2OS lines were established by
selection in medium containing 0.5 mg/ml G418 (Life Technologies).
All chemicals were from Sigma-Aldrich except lambda phosphatase (New
England Biolabs).
Antibodies, SDS-PAGE, and Western Blotting
See the Supplemental Information for antibodies used in this study. SDS-
PAGE and western blotting were performed as described previously (Polo
et al., 2012).
Plasmids, siRNAs and Transfections
See the Supplemental Information for plasmids and siRNAs used in this study.
Plasmids were transfected into DT40 by electroporation and human cells using
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s in-
structions. Small interfering RNAs (siRNAs) were transfected using Lipofect-
amine RNAiMAX (Life Technologies) according to the manufacturer’s
instructions.ular Cell 57, 1133–1141, March 19, 2015 ª2015 Elsevier Inc. 1139
Adenovirus Infections
Adenovirus infections were carried out as described (Blackford et al., 2008).
The hr703 E1B mutant adenovirus was used rather than wild-type virus,
because one of the E1B gene products induces BLM degradation (Orazio
et al., 2011).
Immunoprecipitations
For preparation of lysates for immunoprecipitations (IPs), cells were washed
twice in phosphate-buffered saline (PBS) and lysed in IP buffer (100 mM
NaCl, 0.2% Igepal CA-630, 1 mM MgCl2, 10% glycerol, 5 mM NaF, 50 mM
Tris-HCl [pH 7.5]), supplemented with Complete EDTA-free protease inhibitor
cocktail (Roche) and 25 U/ml Benzonase (Novagen). After nuclease digestion,
NaCl and EDTA concentrations were adjusted to 200 mM and 2 mM, respec-
tively, and lysates were cleared by centrifugation. Where appropriate, anti-
bodies were added to a final concentration of 1 mg/mg lysate and incubated
for 2 hr at 4C. Lysates were then incubated with 10 ml of either GFP-Trap
agarose beads (ChromoTek), anti-Flag M2 affinity gel (Sigma-Aldrich), or pro-
tein G Sepharose (GE Healthcare) for 2 hr with end-to-end mixing at 4C.
Immunoglobulin-antigen complexes were washed extensively before elution
in 23 SDS sample buffer for SDS-PAGE.
Recombinant Protein Purification and Peptide Pull-downs
Glutathione S-transferase (GST) proteins were purified as described (Black-
ford et al., 2008). Biotinylated peptides (Genosphere Biotechnologies) were
bound to streptavidin-coupled Dynabeads M-280 (Life Technologies) before
incubation with HeLa nuclear extracts (CilBiotech) or purified GST proteins
for 2 hr with end-to-end mixing at 4C. Beads were washed with peptide
pull-down buffer (175 mM NaCl, 0.2% Igepal CA-630, 10% glycerol, 5 mM
NaF, 1 mM EDTA, 50 mM Tris-HCl [pH 8.0], and protease inhibitors) before
resuspension in 23 SDS sample buffer for SDS-PAGE. See the Supplemental
Information for peptide sequences.
GST Pull-downs
Pull-downs were performed as described (Wang et al., 2013).
Analyses of DNA Fibers, SCEs, and Chromosomal Aberrations
Cells were prepared for analyses of DNA fibers, SCEs, and chromosomal
aberrations as described (Niedzwiedz et al., 2004; Schwab et al., 2010).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article at http://dx.doi.org/10.
1016/j.molcel.2015.02.012.
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